This trial will test the safety of a new drug, SX-682, in patients with Myelodysplastic Syndromes. The goal is to find the maximum tolerated dose and identify any dose-limiting toxicities.
2 Primary · 6 Secondary · Reporting Duration: Up to 28 days in the 28 day Cycle 1.
Experimental Treatment
64 Total Participants · 1 Treatment Group
Primary Treatment: SX-682 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: